Parnell Pharmaceuticals Holdings Ltd. (PARNF)

[MaineMan5]

'18 guidance had both good and bad to it - good: 30-35% rev growth in '18, $5-6mm EBITDA (about $.30 / share) caompared to breakeven this year, current SP at 2x expected '18 EBITDA, 100% rev growth in contract manufacturing, talk of maximizing shareholder value. Bad: boardroom drama, zydax change of strategy, pipeline uncertainty, some underperforming segments. I feel like even with the uncertainties however, this is a good risk / reward and remains in my speculative portfolio. Plan on holding for a few more quarters to see what transpires as it could be a home run, in any event, I don't see a lot of downside, and could easily be a $2-$3 stock at this time next year.